Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockadeNicolas Jacquelot, Laurence Zitvogel, Takahiro Yamazaki et al.|Cell Research|2019Cited by 246
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Keith T. Flaherty, Florentia Mina et al.|EClinicalMedicine|2023Cited by 26